Skip to main content
. 2021 Jun 4;13:4483–4495. doi: 10.2147/CMAR.S300515

Figure 5.

Figure 5

Ubenimex inhibits GC metastasis by alleviating the activation of the CD13/NAB1/MAPK signaling pathway. (AD) Western blot analyses of MAPK expression in MGC-803, SGC-7901, BGC-823 and MKN-28 human gastric cells treated with 0.12 mg/mL or 0.25 mg/mL of Ubenimex. The column graph shows the relative grayscale value of each band compared with β‑actin. (EH) GC cells were treated with 0.12 mg/mL Ubenimex and then either left non-transfected or transfected with the NAB1 overexpression plasmid. The protein expression levels were then compared between the transfected and non-transfected cells. The column graph shows the relative grayscale value of each band compared with β‑actin. (I and K) The transwell invasion or migration assay with 0.12 mg/mL of Ubenimex or 0.12 mg/mL of Ubenimex added NAB1 overexpression plasmids for MGC-803, SGC-7901, BGC-823 and MKN-28 human gastric cells. Photomicrographs of invaded or migrated tumor cells are shown. Bar =100 µm. (J and L) Column graph of the number of invaded or migrated cells. *P<0.05, **P<0.01 and ***P<0.001; MAPK: mitogen-activated protein kinase.